HomeAI · summaries
Storia in 3 fonti
Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
Novo and Eli Lilly are both trying to shape the narrative of their rival pills, considered to be the start of the next phase of the weight-loss drug era.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market
The FDA approval of Eli Lilly's GLP-1 pill Foundayo comes nearly three months after Novo Nordisk's oral version of Wegovy hit the market.
- ·
upi.com
FDA approves Eli Lilly's GLP-1 weight-loss pill Foundayo - UPI.com
The Food and Drug Administration on Wednesday approved Eli Lilly's pill version of a GLP-1 medication for weight loss.
